Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma

Abstract

BackgroundWe investigated the clinical features and treatment outcomes of patients with mantle cell lymphoma (MCL) in Korea.MethodsWe retrospectively analyzed the clinical characteristics and prognosis of 131 patients diagnosed with MCL between January 2004 and December 2009 at 15 medical centers in Korea; all patients received at least 1 chemotherapeutic regimen for MCL.ResultsThe median age for the patients was 63 years (range, 26-78 years), and 77.9% were men. A total of 105 patients (80.1%) had stage III or IV MCL at diagnosis. Fifty-two patients (39.7%) were categorized with high- or high-intermediate risk MCL according to the International Prognostic Index (IPI). Eighteen patients (13.7%) were in the high-risk group according to the simplified MCL-IPI (MIPI). The overall incidence of extranodal involvement was 69.5%. The overall incidence of bone marrow and gastrointestinal involvements at diagnosis was 41.2% and 35.1%, respectively. Cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab were used frequently as the first-line treatment (41.2%). With a median follow-up duration of 20.0 months (range, 0.2-77.0 months), the overall survival (OS) at 2 years was 64.7%, while the event-free survival (EFS) was 39.7%. Multivariate analysis showed that the simplified MIPI was significantly associated with OS. However, the use of a rituximab-containing regimen was not associated with OS and EFS.ConclusionSimilar to results from Western countries, the current study found that simplified MIPI was an important prognostic factor in Korean patients with MCL.

TCL1 expression predicts overall survival in patients with mantle cell lymphoma

“…However, there was no significant association between MIPI and PFS ( P = 0.061). The results correspond well with those reported by previous studies .…”

Negative prognostic impact of low absolute CD4+ T cell counts in peripheral blood in mantle cell lymphoma

“…Lymphopenia has been reported to be an adverse prognostic factor in some aggressive lymphomas . However, in MCL, BMI is quite common . Cancer cells account for the majority of total lymphocyte counts, so we chose T cell counts and NK cell counts as prognostic factors by flow cytometry in our study.…”

The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective

“…We retrospectively analyzed 131 mantle cell lymphoma (MCL) patients [5]. Their median age was 63 years (range, 26-78 years; male, 77.9%).…”